chufangao/CTO huggingface dataset:
Clinical trial NCT02624869: Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)
Official title: Open-label, Single-Arm, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of Evolocumab for LDL-C Reduction, as Add-on to Diet and Lipid-lowering Therapy, in Pediatric Subjects From 10 to 17 Years of Age With Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH)
Acronym: HAUSER-OLE
Sponsor: Amgen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 163.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-09-10
Primary completion date: 2021-06-01
Completion date: 2021-06-01
Baseline population: All enrolled participants
Plan to share individual participant data: YES
IPD sharing description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
IPD time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
IPD access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Clinical trial NCT05215418: A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese Subjects
Official title: A Multicenter, Randomized, Double-Blind Study to Compare the Effects of VI-0521,Phentermine, and Placebo on Ambulatory Blood Pressure in Overweight or Obese Subjects
Sponsor: VIVUS LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 565.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-01-25
Primary completion date: 2023-04-11
Completion date: 2023-04-17
Limitations and caveats: Participants with baseline blood pressure greater than 140/90 were excluded. Of the 565 total participants randomized and treated with study drug, 180 participants were excluded from the per protocol population used for the primary analysis due to participants' reluctance or inability to properly complete end of study ABPM assessments.
Clinical trial NCT03801265: Lumbar Plexus vs Quadratus Lumborum Block in Post-operative Pain Following Total Hip Replacement
Official title: A Prospective, Randomized, Double-blinded, Active-comparator, Non-inferiority Study to Observe Relative Efficacy of Ultrasound-guided Transmuscular Quadratus Lumborum Block Versus Class Lumbar Plexus Block in Managing Post-operative Pain Following Total Hip Replacement Surgery
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 46.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-03-19
Primary completion date: 2020-05-30
Completion date: 2020-05-30
Limitations and caveats: The study was conducted at a single-center, potentially confounding external validity. Though the desired statistical power was achieved, our sample was still small. More non-inferiority studies are needed to confirm our results.
Plan to share individual participant data: NO
Clinical trial NCT02590523: Intracameral Antibiotic Safety Study
Official title: Intracameral Antibiotic Safety Study
Sponsor: Panhandle Eye Group, LLP (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: SUSPENDED 
Why stopped: Lack of antibiotic availability
Enrollment: 500.0 (ESTIMATED)
Number of arms: 3.0
Start date: 2023-01-31
Primary completion date: 2024-01-31
Completion date: 2024-01-31
Clinical trial NCT02987998: Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC
Official title: A Phase I Safety and Feasibility Study of Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in Resectable Stage 3A Non-Small Cell Lung Cancer
Sponsor: Case Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: higher than expected rate of toxicity \& unrealistic timeline to complete trial under company's proposed plan to reopen
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-05-19
Primary completion date: 2022-11-28
Completion date: 2022-11-28
Clinical trial NCT02774681: Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis
Official title: A Phase II Single Arm Study of Palbociclib in Patients With Metastatic HER2-positive Breast Cancer With Brain Metastasis
Sponsor: Northwestern University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow accrual
Enrollment: 12.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-08-31
Primary completion date: 2019-02-13
Completion date: 2020-02-16
Limitations and caveats: The study was closed before the accrual goal was met due to slow accrual.
Clinical trial NCT04530877: Exclusive Enteral Nutrition vs. Infliximab in Chinese CD Patients
Official title: Comparative Effectiveness of Exclusive Enteral Nutrition and Infliximab in Chinese Children With Active Crohn's Disease
Sponsor: Children's Hospital of Fudan University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: no funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-10-01
Primary completion date: 2024-09-30
Completion date: 2024-09-30
Clinical trial NCT03837353: A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1
Official title: A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1
Sponsor: NYU Langone Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Terminated early due to slow accrual in the context of changing practice patterns.
Enrollment: 18.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-04-01
Primary completion date: 2022-07-19
Completion date: 2022-09-20
Plan to share individual participant data: YES
IPD sharing description: Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
IPD time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
IPD access criteria: The investigator who proposed to use the data.
Clinical trial NCT02987959: Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas
Official title: Phase II Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas With Dysregulation of the mTOR Pathway
Sponsor: Fox Chase Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Closed to accrual due to Funding Sponsor withdrawing support due to low accrual
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-02-21
Primary completion date: 2019-01-30
Completion date: 2020-07-24
Clinical trial NCT04661514: Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy
Official title: Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy
Sponsor: University of California, San Diego (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 16.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-05-01
Primary completion date: 2022-03-10
Completion date: 2022-06-10
Clinical trial NCT05181540: A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation
Official title: A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)
Acronym: E-CELERATE
Sponsor: Angiocrine Bioscience (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Interim analysis showed lack of efficacy
Enrollment: 130.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-02-21
Primary completion date: 2023-12-29
Completion date: 2024-01-24
Plan to share individual participant data: NO
Clinical trial NCT04280588: Fingolimod in COVID-19
Official title: Efficacy of Fingolimod in the Treatment of New Coronavirus Pneumonia (COVID-19)
Sponsor: First Affiliated Hospital of Fujian Medical University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No participants enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-22
Primary completion date: 2020-07-01
Completion date: 2020-07-01
Plan to share individual participant data: YES
Clinical trial NCT05016622: Booster Dose Trial
Official title: Safety and Efficacy of Booster Doses of COVID-19 Vaccine in Immunocompromised Patients With a Cancer Diagnosis
Sponsor: Montefiore Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to decreased level of engagement and available funding, PI determined it appropriate to close the study prior to visit occurring. IRB approved.
Enrollment: 106.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-08-10
Primary completion date: 2022-04-20
Completion date: 2023-05-21
Baseline population: 106 participants were enrolled into the study.
Plan to share individual participant data: NO
Clinical trial NCT05363605: A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
Official title: A Phase 1/2 Study of [225Ac]-FPI-1966, [111In]-FPI-1967, and Vofatamab in Participants With FGFR3-expressing Advanced, Inoperable, Metastatic and/or Recurrent Solid Tumours
Sponsor: Fusion Pharmaceuticals Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Fusion announced that it is discontinuing this study as part of a portfolio prioritization and assessment; Fusion no longer plans to pursue development of FPI-1966.
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-04-20
Primary completion date: 2023-09-08
Completion date: 2023-09-08
Clinical trial NCT03311126: Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma
Official title: Bendamustine + Obinutuzumab Induction Chemoimmunotherapy With Risk-adapted Obinutuzumab Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma
Sponsor: University of Wisconsin, Madison (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: slow accrual
Enrollment: 21.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-10-19
Primary completion date: 2023-07-31
Completion date: 2023-07-31
Plan to share individual participant data: NO
Clinical trial NCT04733157: The Efficacy of Tranexamic Acid in Preventing Postpartum Haemorrhage After Caesarean Section
Official title: The Efficacy of Tranexamic Acid in Preventing Postpartum Haemorrhage After Caesarean Section
Acronym: ETAPPH
Sponsor: University of Zimbabwe (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1226.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-23
Primary completion date: 2021-12-14
Completion date: 2021-12-14
Plan to share individual participant data: NO
IPD sharing description: It is not yet known if there will be a plan to make individual patient data (IPD) available.
Clinical trial NCT03548584: A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type
Official title: A Phase 3, 12-Week, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-Arm, Fixed-dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 345.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-05-16
Primary completion date: 2022-05-23
Completion date: 2022-06-01
Baseline population: Randomized Sample consisted of all participants who were randomized into this trial.
Plan to share individual participant data: YES
IPD sharing description: Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
IPD time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
IPD access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/
Clinical trial NCT04100018: A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer
Official title: A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer
Acronym: CheckMate 7DX
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1030.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-06
Primary completion date: 2023-06-01
Completion date: 2024-06-25
Clinical trial NCT04512911: Comparison of Ventricular Tachycardia Ablation Strategies in Patients With Ischemic Cardiomyopathy
Official title: Endocardial-Epicardial Radiofrequency Ablation of Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy
Acronym: EPI-VT
Sponsor: Montefiore Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: IRB approval expired 1/23/2023 and eclipsed the 6 month institutional window where study can be reinitiated via progress report. No enrollment has taken place.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-01-31
Primary completion date: 2023-01-23
Completion date: 2023-01-23
Plan to share individual participant data: NO
Clinical trial NCT04984278: Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis
Official title: A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients With Multiple Sclerosis
Acronym: RELEASE MSS5
Sponsor: Jazz Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The study was terminated based on a business decision by the Sponsor.
Enrollment: 56.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-08-16
Primary completion date: 2022-11-11
Completion date: 2022-11-11
Baseline population: Baseline characteristics were assessed in the Full Analysis Set.
Plan to share individual participant data: NO
Clinical trial NCT03325166: Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases
Official title: The Use of Perfusion MRI Using Ferumoxytol and Small Molecular Weight Gadolinium (Gd) Agents to Assess Response to Pembrolizumab in Brain Metastases and Systemic Lesions in NSCLC: A Comparison of Imaging Modalities to Address Brain Metastases, Pseudoprogression, and Systemic Lesion Tumor Flare (Neuro-Check Pilot)
Sponsor: OHSU Knight Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low accrual
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-11-03
Primary completion date: 2021-03-01
Completion date: 2021-03-01
Limitations and caveats: Due to very low enrollment and staffing issues, data was not collected for analysis of study outcomes.
Clinical trial NCT03686696: Randomized Evaluation of Beta Blocker and ACEI/ARB Treatment in MINOCA Patients - MINOCA-BAT
Official title: Randomized Evaluation of Beta Blocker and Angiotensin Converting Enzyme Inhibitor (ACEI) /Angiotensin Receptor Blocker (ARB) Treatment in MINOCA Patients.
Acronym: MINOCA-BAT
Sponsor: Uppsala University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Low inclusion rate.
Enrollment: 198.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-12-16
Primary completion date: 2023-05-31
Completion date: 2023-08-22
Plan to share individual participant data: YES
IPD sharing description: We will make a limited, de-identified set of data available for researchers outside the primary investigators two years after the publication of the primary results of the study. Before data are shared, a data-sharing agreement should be established documenting what data are being shared and how the data can be used. The agreement serves two purposes. First, it protects the agency providing the data, ensuring that the data will not be misused. Second, it prevents miscommunication on the part of the provider of the data and the agency receiving the data by making certain that any questions about data use are discussed. The following items should be covered in the data-sharing agreement:~* Period of agreement~* Intended use of the data~* Constraints on use of the data~* Data confidentiality~* Data security~* Methods of data-sharing
Clinical trial NCT03182894: Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer
Official title: A Phase IB/II Study of Epacadostat (INCB024360) in Combination With Pembrolizumab (MK-3475) and Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Study will not be conducted due to changes related to the investigational agent.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-09-30
Primary completion date: 2019-07-30
Completion date: 2020-07-30
Plan to share individual participant data: NO
Clinical trial NCT02438852: Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer
Official title: Efficacy of Continuous Infusion of Local Anesthesia After Radical Cystectomy: A Randomized, Double Blind, Placebo Controlled Study
Sponsor: University of Southern California (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: No funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-25
Primary completion date: 2021-02-25
Completion date: 2022-02-25
Clinical trial NCT04586244: An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma
Official title: An Open-Label, Randomized, Phase 2, Umbrella Study to Investigate the Biological Rational of Various Neoadjuvant Therapies for Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Cisplatin-Ineligible or Refuse Cisplatin Therapy and Undergoing Radical Cystectomy
Acronym: Optimus
Sponsor: Incyte Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Business Decision. No safety concerns contributed to this decision.
Enrollment: 30.0 (ACTUAL)
Number of arms: 5.0
Start date: 2022-01-14
Primary completion date: 2024-01-29
Completion date: 2024-01-29
Plan to share individual participant data: YES
IPD sharing description: Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
IPD time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
IPD access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Clinical trial NCT04358068: Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19
Official title: A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow enrollment and lack of community enthusiasm
Enrollment: 20.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-13
Primary completion date: 2020-07-08
Completion date: 2020-07-08
Baseline population: Participants who initiated study treatment
Limitations and caveats: The study was terminated early due to slow enrollment and lack of community enthusiasm. Follow-up through week 24 was not completed for any participant. Participants were asked to complete the Day 20 visit and then were discontinued from the study.
Plan to share individual participant data: YES
IPD sharing description: Individual participant data that underlie results in the publication, after deidentification.
IPD time frame: Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.
IPD access criteria: * With whom?~  * Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.~* For what types of analyses?~  * To achieve aims in the proposal approved by the AIDS Clinical Trials Group.~* By what mechanism will data be made available?~  * Researchers may submit a request for access to data using the AIDS Clinical Trials Group Data Request form at: https://submit.mis.s-3.net/ Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.
Clinical trial NCT01280669: Intravitreal Sirolimus as Therapeutic Approach to Uveitis
Official title: Sirolimus as a Therapeutic Approach for Uveitis: A Phase 2, Open-label, Randomized Study to Assess the Safety, Tolerability, and Bioactivity of Two Doses of Intravitreal Injection of Sirolimus in Patients With Non-infectious Uveitis
Acronym: SAVE-2
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Never started due to sponsor decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-09-30
Primary completion date: 2024-09-30
Completion date: 2024-12-31